第三代化疗方案联合重组人血管内皮抑制素治疗晚期非小细胞肺癌的Meta分析  

A Meta-analysis of Third-generation Chemotherapy Regimen Combined Endostatin on Treatment of Advanced Non-small-Cell Lung Cancer

作　　者：陈宇[1] 戈伟[1] 袁丽[2] 

机构地区：[1]武汉大学人民医院肿瘤中心,湖北武汉430060 [2]湖北医药学院,湖北十堰442000

出　　处：《郧阳医学院学报》2011年第2期145-149,共5页Journal of Yunyang Medical College

摘　　要：目的:使用Meta分析评价以第三代化疗方案联合重组人血管内皮抑制素(YH-16)治疗晚期非小细胞肺癌(NSCLC)的疗效。方法:检索第三代化疗方案联合YH-16治疗晚期NSCLC的随机对照临床实验,对符合标准的文献进行质量评价,使用Review Manager 5进行Meta分析。结果:12篇文献(616例患者)符合入选标准。联合化疗方案与单纯化疗方案组在部分缓解率(PRR)、疾病控制率(DCR)、疾病进展(PD)上存在差异(OR=2.20,95%CI=1.56～3.09,P=0.98;OR=2.20,95%CI=1.48～3.28,P=0.97;OR=0.46,95%CI=0.31～0.69,P=0.97)。结论:治疗晚期NSCLC使用联合方案组优于单纯化疗方案组。Objective To analyze the effective of third generation chemotherapy regimen combined with recombinant human endothelium inhibitor(endostatin) on treatment of advanced non-small-cell lung cancer(NSCLC) by Meta-analysis.Methods The literatures about clinical randomized controlled trial of third-generation chemotherapy regimen combined endostatin in treatment of advanced NSCLC were searched in the database,the quality evaluation were carried out in selected literatures by Review Manager 5 software.Results Total 12 literatures including 616 cases of patients were selected.The partial response rate(PRR),disease control rate(DCR) and disease progression in endostatin combined third-generation chemotherapy group and single third-generation chemotherapy group were significant difference(OR=2.20,95%CI=1.56～3.09,P=0.98;OR=2.20,95%CI=1.48～3.28,P=0.97;OR=0.46,95%CI=0.31～0.69,P=0.97).Conclusion The third generation chemotherapy regimen combined with recombinant human endothelium inhibitor could be better than single third generation chemotherapy regimen in the treatment of advanced non-small-cell lung cancer.

关 键 词：晚期非小细胞肺癌 化学治疗 重组人血管内皮抑制素/YH-16 META分析 

分 类 号：R734.2[医药卫生—肿瘤]